The mechanism of estrogen-mediated neuroprotection is not yet clear. Estrogens have a variety of modes of action, including transducing signaling events such as activation and/or suppression of the mitogen-activated protein kinase (MAPK) pathway. We have previously shown protein phosphatases to be involved in 17␤-estradiol-mediated neuroprotection. In the present study, we assessed the role of estrogen receptors (ERs) in estrogen-mediated neuroprotection from oxidative/excitotoxic stress and the consequential effects on MAPK signaling. Okadaic acid and calyculin A, nonspecific serine/threonine phosphatase inhibitors, were exposed to cells at various concentrations in the presence or absence of 17␣-estradiol, the enantiomer of 17␤-estradiol, 2-(1-adamantyl)-3-hydroxyestra-1,3,5(10)-trien-17-one (ZYC3; non-ER-binding estrogen analog), and/or glutamate. All three compounds, which we have shown to have little or no binding to ER␣ and ER␤, were protective against glutamate toxicity but not against okadaic acid and calyculin A toxicity. In addition, in the presence of effective concentrations of these inhibitors, the protective effects of these estrogen analogs were lost. Glutamate treatment caused a 50% decrease in levels of protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A), and protein phosphatase 2B (calcineurin) (PP2B). Coadministration of ZYC3 with glutamate prevented the decreases in PP1, PP2A, and PP2B levels. Furthermore, glutamate treatment caused a persistent increase in phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 that corresponds with the decrease protein levels of serine/threonine phosphatases. ZYC3 blocked this persistent increase in ERK phosphorylation. These results suggest that estrogens protect cells against glutamate-induced oxidative stress through an ER-independent mediated mechanism that serves to preserve phosphatase activity in the face of oxidative insults, resulting in attenuation of the persistent phosphorylation of ERK associated with neuronal death.
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Estrogens have been shown to be potent neuroprotectants in a variety of systems and experimental models of neurodegeneration and cerebral ischemia (Gridley et al., 1997; Simpkins et al., 1997; Dubal et al., 1998; Green et al., 1998; Green and Simpkins, 2000; Yang et al., 2001) . However, the mechanism of action remains elusive. Potential mechanisms of estrogens' neuroprotective effects include the following: 1) classical estrogen receptor (ER)-dependent genomic actions; 2) ER-dependent, nongenomic actions; 3) ER-independent genomic actions; and 4) ER-independent nongenomic actions.
This laboratory and others have demonstrated that estrogens exert potent neuroprotective effects at physiologically relevant concentrations (for review, see Green and Simpkins, 2000) . Both the naturally occurring feminizing estrogen, 17␤-estradiol, and its inactive isomer, 17␣-estradiol, can reduce toxicity caused by serum deprivation, ␤-amyloid treatment, and exposure to glutamate receptor agonists in cell model systems (Gridley et al., 1997 Green et al., 1998; Zaulyanov et al., 1999) . In addition, this laboratory has also demonstrated that treatment with either 17␣-estradiol or enantiomer of 17␤-estradiol (ENT E2) markedly reduces ischemic brain damage produced by middle cerebral artery occlusion in ovariectomized rats Yang et al., 2000; Yang et al., 2001 ) and that estradiol administration reduces secondary ischemic damage and mortality after subarachnoid hemorrhage in vivo ). ZYC3, a nonreceptor-binding estrogen analog, possesses both neuroprotective and vasoactive effects, which offers the possibility of clinical application for stroke without the side effects of estrogens (Liu et al., 2002) . It also suggests that both the neuroprotective and vasoactive effects of estrogen are receptor independent because estrogen analogs with little or no binding to ER␣ and ER␤ have been shown to be neuroprotective (Liu et al., 2002; Perez et al., 2005) . In many studies, ER antagonists do not block or attenuate the protective actions of 17␤-estradiol (Weaver et al., 1997; Moosmann and Behl, 1999) , and estrogens exert their neuroprotective action even in the presence of transcription and translation inhibitors (Regan and Guo, 1997; Sawada et al., 1998) . Furthermore, estrogens are known to activate ERK1/2 within 5 to 15 min, and this activation persists for at least 2 h (Singh et al., 2000) . It has been speculated that the time course of ERK activation, among other factors, determines whether a cell commits to survival or death, which can explain the contradictory effects of MEK1/2 inhibition on neuronal cell survival.
Persistent activation of ERK has been shown to be involved in neuronal cell death (Alessandrini et al., 1999; Wang et al., 2003 Wang et al., , 2004 . Aberrant neuronal expression of phosphorylated ERK1/2 and other MAPKs are seen in brains with Alzheimer's disease (Zhu et al., 2002b) and other neurodegenerative diseases characterized by deposits (Ferrer et al., 2003) . In patients with Parkinson's disease, increased phosphorylation of ERK is seen in the substantia nigra and midbrain (Zhu et al., 2002a) . After acute ischemic stroke, there is an increased ERK phosphorylation in the penumbra (Slevin et al., 2000) .
In the present study, we hypothesized that the neuroprotective actions of estrogens do not require receptor binding but the activation of phosphatases to mediate signaling through the MAPK pathway. We have previously shown that serine/threonine phosphatases are involved in neuroprotective mechanism of 17␤-estradiol (Yi et al., 2005) . We show that inhibition of serine/threonine protein phosphatases attenuates the neuroprotective effects of estrogen analogs that have little or no ER␣-or ER␤-binding properties and involves the MAPK signaling pathway.
Materials and Methods
Chemicals. 17␣-Estradiol was purchased from Steraloids, Inc. (Wilton, NH). ZYC3 and ENT E2 were prepared as described previously (Green and Simpkins, 2000; Liu et al., 2002) . All steroids were dissolved in dimethyl sulfoxide at a concentration of 10 mM and diluted to appropriate concentrations in culture media. Calcein AM was purchased from Molecular Probes, Inc. (Eugene, OR). Okadaic acid, L-glutamate, and dimethyl sulfoxide were purchased from Sigma-Aldrich (Paris, KY). Calyculin A and PD98059 were purchased from Calbiochem (San Diego, CA). Anti-PP1, anti-PP2A, anti-PP2B, anti-ERK, and anti-pERK were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Culture of Primary Cortical Neurons. Embryonic rat cerebral cortex (18 days) were dissected and harvested in preparation medium (DMEM; 4.5 g/l glucose, 100 U/ml penicillin, 100 g/ml streptomycin). The cortical tissue was treated with trypsin. The tissue was washed three times using washing medium (Hanks' medium; 4.5 g/l glucose, 100 U/ml penicillin, 100 g/ml streptomycin), and individual cells were isolated by mechanical trituration using three different sizes of fire-polished Pasteur pipettes. The cells were harvested in seeding medium (DMEM; 4.5 g/l glucose, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine, 19% horse serum) and filtered through a 40-m filter. The cerebral cortical cells were seeded in various poly-L-lysine-treated dishes and plates at various cell densities. The cells were incubated in neurobasal medium (DMEM, 4.5 g/l glucose, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine) supplemented with B-27 with antioxidants in normal cell culture condition of 37°C in a humid atmosphere of 5% CO 2 . Primary cortical neurons were maintained in culture for 7 days before initiation of various experiments. Two hours before treatment with various inhibitors and/or 17␣-estradiol, ENT E2, or ZYC3, the media were replaced with neurobasal medium supplemented with B-27 without antioxidants.
Calcein-AM Viability Assay. Primary cortical neurons were exposed to various treatments. After exposure to various treatment paradigms, cells were rinsed with phosphate-buffered saline, and cell viability was measured using the membrane-permeant calcein-AM dye (Molecular Probes). Calcein-AM is a fluorogenic esterase substrate that is hydrolyzed to a fluorescent product in cells having esterase activity and intact membranes. Cells were incubated in a solution of 2.5 M calcein-AM in phosphate-buffered saline. Twenty minutes later, fluorescence was determined using a Bio-Tek FL600 microplate reader (Bio-Tek Instruments, Winooski, VT) with an excitation/emission filter set of 485/530 nm, respectively. Cell culture wells treated with methanol served as blanks. The results, obtained in relative fluorescent units, are expressed as the percentage of untreated or vehicle-treated control values.
Immunoblot Analysis. Protein from whole cell lysates (25 g) was separated by SDS-polyacrylamide gel electrophoresis and transferred to Immunobilon-P polyvinylidene difluoride (Millipore Corp., Bedford, MA) membrane. Membranes were rinsed in Tris-buffered saline (10 mM Tris-base, pH 8.0, 100 mM NaCl) containing 0.2% Tween 20, then blocked with 3% bovine serum albumin. Blots were then incubated with primary antibodies overnight at 4°C, rinsed, and incubated in the appropriate secondary antibody before detection using enhanced chemiluminescence (Pierce Biotechnology, Inc., Rockford, IL). Enhanced chemiluminescence results were digitized and quantified using the UVP Bioimaging System. The immunoblots for protein phosphatases were normalized to ␤-actin and for pERK1/2 to ERK2 to ensure equal protein loading, and these normalized data were presented as percentage of control (100%).
Data Analysis. Statistical significance was determined by oneway analysis of variance followed by a Tukey's multiple comparison test. p Ͻ 0.05 was considered significant for all experiments. The values are reported as the mean Ϯ S.E.M.
Results

Effects of PP Inhibitors on Estrogen Analog-Mediated
Neuroprotection against Glutamate-Induced Cytotoxicity. Estrogen analogs such as 17␣-estradiol, ENT E2, and ZYC3 (structures in Fig. 1 ) have been shown to be as potent neuroprotectants as 17␤-estradiol (Bishop and Simpkins, 1994; Green et al., 2001; Perez et al., 2005) . To determine the effectiveness of 17␣-estradiol, ENT E2, and ZYC3 to protect neurons against oxidative stress or excitotoxicity induced by glutamate in the presence of a serine/threonine phosphatase inhibitor, we examined simultaneous treatment as well as 2-or 24-h pretreatment of 17␣-estradiol, ENT E2, or ZYC3 with glutamate and/or okadaic acid or calyculin A. In the absence of protein phosphatase inhibitors, the three estrogen analogs showed a dose-dependent neuroprotection against glutamate toxicity (Fig. 2) . ZYC3 showed a greater potency then either ENT E2 or 17␣-estradiol, consistent with our previous structure-activity relationship assessment (Perez et al., 2005) . 17␣-Estradiol, ENT E2, and ZYC3 were ineffective against okadaic acid or calyculin A toxicity when the serine/threonine inhibitor was ER Receptor-Independent Neuroprotection simultaneously administered with the steroids. In addition, nonlethal concentrations of okadaic acid or calyculin A attenuated the ZYC3-mediated neuroprotection against glutamateinduced toxicity (Fig. 3) . Nearly complete abolishment of estrogen analog protection against glutamate toxicity was seen at 5 nM okadaic acid and 0.5 nM calyculin A (Fig. 3, A and B, respectively). Twenty-four-hour ZYC3 pretreatment did not prevent protein phosphatase inhibitor-induced cell death or the protein phosphatase inhibitor-induced abolishment of protection by ZYC3 of glutamate-induced neurotoxicity (Fig. 4) . Data from 2-h pretreatment of ZYC3 or 24-and 2-h pretreatment with ENT E2 or 17␣-estradiol are not shown, but the results were similar to those seen with the 24-h pretreatment with ZYC3.
Time-Dependent Effects of ZYC3 and/or Glutamate on PP1 Protein Level. We examined the time course of the re- sponse of serine/threonine phosphatase protein expressions to treatment with glutamate and/or ZYC3. Glutamate treatment caused a 50% reduction in PP1 protein levels that was significant at 15 min and persisted through 24 h of treatment (Fig.  5A ). ZYC3 alone did not significantly alter the expression of PP1 at any given time point compared with nontreated controls (Fig. 5B) . However, simultaneous treatment with ZYC3 and glutamate caused a rapid and profound increase in PP1 expression at 30 min and 1 h followed by a return to control levels after 2 h post-treatment that persists to 24 h post treatment (Fig.  5C ). The time course and magnitude of the response to ZYC3 was similar to that which we have reported for 17␤-estradiol (Yi et al., 2005) . Similar trends were seen with PP2A and PP2B expression (data not shown). PP2A and PP2B protein expressions were decreased to ϳ30 to 50% by 1 h after glutamate treatment, and this effect persisted for 24 h. The presence of ZYC3 in the face of glutamate challenge caused a transient increase in PP2A and PP2B protein levels by 3-to 4-fold within 15 to 30 min. PP2A and PP2B protein levels return to control levels by 1 h post-treatment and remained at control levels at 24 h post-treatment.
Effects of Estrogen Analogs on PP1, PP2A, and PP2B Protein Expression. To determine the effects of ZYC3 treatment on protein phosphatase expressions, we examined protein expressions of PP1, PP2A, and PP2B after 24-h simultaneous treatment of glutamate, okadaic acid, and/or ZYC3 in cortical neurons. Twenty-four-hour treatment of cortical neurons with ZYC3 alone did not alter levels of PP1 (Fig. 6A), PP2A (Fig. 6B), and PP2B (Fig. 6C ) compared with nontreated control cells. However, 24-h glutamate treatment caused a marked decrease in protein levels of PP1, PP2A, and PP2B (Fig. 6, A-C ). Simultaneous treatment with 10 nM ZYC3 in the presence of 50 M glutamate restored PP1, PP2A, and PP2B protein expression to levels comparable with untreated control cells (Fig. 6, A-C) . However, ZYC3 treatment was unable to block the glutamate-induced decrease in protein expressions of PP1, PP2A, and PP2B in the presence of okadaic acid (Fig. 6, A-C) .
MEK-Dependent Neuroprotection against Toxicity. Experimental data have shown that inhibition of ERK phosphorylation via MEK inhibition is neuroprotective (Chu et al., 2004) . Hence, the neuroprotective effects of MEK inhibitors PD98059 (Fig. 7A) or U0126 (Fig. 7B) were evaluated against glutamate toxicity. One-hour pretreatment with PD98059 or U0126 had a neuroprotective effect against cytotoxicity caused by glutamate. This MEK-inhibitor-induced neuroprotection was blocked by increasing concentrations of okadaic acid (Fig. 7) .
Effects of ZYC3 on ERK Phosphorylation during Oxidative Stress. Chronic phosphorylation of ERK1/2 is thought to send a neurotoxic or neurodegenerative signal (Stanciu et al., 2000; Kulich and Chu, 2001; Zhu et al., 2002a) ; thus, it has been speculated that estrogens attenuate the persistent ERK1/2 phosphorylation to mediate neuroprotection. Therefore, we examined the phosphorylation of ERK1/2 in glutamate toxicity in the presence of ZYC3 and/or okadaic acid. Twenty-four hour glutamate treatment caused an ϳ2.5-fold increase in phosphorylation of ERK1/2 (Fig. 8) . ZYC3 alone did not alter the phosphorylation state of ERK1/2 compared with vehicle control (Fig.  8) . However, the presence of ZYC3 attenuated the elevated phosphorylation of ERK1/2 induced by glutamate. The presence of ZYC3 had no effect on okadaic acid-induced ERK1/2 phosphorylation, and the presence of okadaic acid abolished the ZYC3-mediated reduction in phosphorylation ERK1/2 caused by glutamate (Fig. 8) .
Discussion
The present study demonstrates that one of the mechanisms of estrogen-mediated neuroprotection is preservation of serine/threonine phosphatase protein expression via an ER-independent pathway that ultimately prevents persistent ERK1/2 phosphorylation. These observations are important in view of the Women's Health Initiative Memory Study results that indicate chronic postmenopausal treatment of older women with estrogens Espeland et al., 2004) does not protect the brain from dementia but seems to cause an increase in strokes, heart attacks, deep venous thromboses, and suddenonset dementia through a mechanism that likely involves induction of a hypercoagulative state through peripheral stimulation of prothrombotic and a decrease in antithrombotic factors (Hoibraaten et al., 2001; Scarabin et al., 2003; Canonico et al., 2007) , some of which are known to be ERmediated. Thus, alternatives to feminizing estrogens that protect the brain are needed.
We have previously reported that the nonfeminizing analogs of estrogens used in this study are protective against a variety of cytotoxic insults as well as in a jpet.aspetjournals.org rat model for middle cerebral artery occlusion Yang et al., 2000; Liu et al., 2002) . The protective effects of these estrogen analogs against glutamate toxicity were antagonized by the protein phosphatase inhibitors, okadaic acid and calyculin A. In addition, we show that estrogen analogs rapidly and persistently antagonize the reduction in PP1, PP2A, and PP2B protein expression induced by oxidative and excitotoxic stresses, but not in the presence of okadaic acid. Phosphorylation of ERK1/2 in response to glutamate toxicity corresponds to decreases in serine/threonine phosphatase expression, and inhibitors of ERK1/2 phosphorylation attenuate the glutamate-induced cytotoxicity. Taken together, these data support the hypothesis that phosphatase regulation is a major component of estrogen-mediated neuroprotection that is not dependent upon the classical ERmediated genomic effects.
Of the three estrogen analogs assessed, ZYC3 was more potent than either 17␣-estradiol or ENT E2, consistent with our previous structure activity relationship studies (Green et al., 2001; Liu et al., 2002; Perez et al., 2005) . Despite this, okadaic acid and calyculin A were effective in blocking the neuroprotective effects of all three compounds. This antagonism by protein phosphatase inhibition of estrogen neuroprotection occurred even at concentrations of okadaic acid and calyculin A that did not induce cell death. This latter observation indicates that abolition of estrogen neuroprotection by protein phosphatase inhibition is not due to an increase in the magnitude of the neurotoxic insult, which we have shown reduces the potency of estrogen neuroprotection (Perez et al., 2005) .
The mechanism of this effect of estrogens on protein phosphatase levels and activity is not clear. There are no previous experimental data suggesting a direct interaction between estrogens and serine/threonine phosphatases. Although PP2A has been shown to regulate ER␣ by mRNA stabilization (Keen et al., 2005) as well as direct interaction with ER␣ in the absence of estrogen (Lu et al., 2003) , our data indicate that effects of estrogens on protein phosphatases occur without ER interactions. An interesting but yet unexplained observation is that although 17␤-estradiol (Yi et al., 2005) or ZYC3 (present study) alone have little effect on protein phosphatase levels, they cause a prompt increase in protein phosphatase concentrations and a persistent resistance to glutamate-induced decline in serine/threonine phosphatase levels. The absence of effects of estrogens alone and the rapidity of the response to estrogens in the face of insult suggest that estrogens either reduce or prevent the clearance of these serine/threonine phosphatases that are activated by oxida- In view of the relative lack of binding of these analogs to ER␣ or ER␤ (Perez et al., 2005) , intracellular signaling pathways may be involved in mediating their neuroprotective effects. Indeed, experimental studies have shown that the neuroprotective effects of estrogens are mediated at least in part through the rapid but acute phosphorylation of signaling proteins, such as adenylyl cyclase, protein kinase B, protein kinase A, protein kinase C, and MAPK (Migliaccio et al., 1996; Watters et al., 1997; Kelly et al., 1999; Zhang et al., 2001) . Changes in the activity of these enzymes can regulate the phosphorylation of numerous intermediary signaling proteins such as protein of 90-kDa ribosomal S6 kinase, p38, c-Jun NH 2 -terminal kinase, and the nuclear transcriptional factors cAMP-response element-binding protein and c-fos/ c-Jun, which may ultimately mediate cell survival (for review, see Lee and McEwen, 2001 ). The present study shows that ERK1/2 is rapidly and persistently phosphorylated in response to oxidative and excitotoxic stresses caused by glutamate, and the presence of estrogens prevents this persis- , and their combination (C) on PP1 protein expression. Primary rat cortical neurons were treated with 50 M glutamate and/or 10 nM ZYC3. Cells were harvested at the times indicated for Western blot analysis of PP1. The immunoblots for protein phosphatases were normalized to ␤-actin to ensure equal protein loading, and these normalized data were used to depict the data as percentage of control (100%). Depicted are mean Ϯ S.E.M. for n ϭ 5. ‫,ء‬ p Ͻ 0.05 versus time 0 control. Fig. 6 . PP1 (A), PP2A (B), and PP2B (C) protein levels in response to ZYC3 in the presence and absence of 50 M glutamate and/or 50 nM okadaic acid in primary rat cortical neurons. Primary cortical neurons were treated with 50 nM okadaic acid (OA), 50 M glutamate (Glut), and/or 10 nM ZYC3. Cells were harvested after 24 h of treatment for Western blot analysis of PP1, PP2A, and PP2B. The immunoblots for protein phosphatases were normalized to ␤-actin to ensure equal protein loading, and these normalized data were used to depict the data as percentage of control (100%). Depicted are mean Ϯ S.E.M. for n ϭ 5. ‫,ء‬ p Ͻ 0.05 versus control; †, p Ͻ 0.05 versus glutamate-treated group.
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at ASPET Journals on October 18, 2017 jpet.aspetjournals.org tent phosphorylation. These data suggests that prolonged phosphorylation of ERK1/2 is detrimental to cell survival, which is supported by the observations by Smith and colleagues (Zhu et al., 2002b) who noted that aberrant neuronal expression of phosphorylated ERK1/2 and other MAPKs in Alzheimer's disease brains is associated with markers of oxidative stress. Others have also shown that MAPK phosphorylation is associated with a variety of sporadic and familial neurodegenerative diseases characterized by deposits (Ferrer et al., 2003) . Patients with Parkinson's disease and other Lewy body diseases have increased phosphorylated ERK1/2 in neurons of substantia nigra and midbrain (Zhu et al., 2002a) . In addition, increased ERK1/2 phosphorylation has been noted in the vulnerable penumbra after acute ischemic stroke in humans (Slevin et al., 2000) .
The present study provides a potential ER-independent mechanism for the neuroprotective effects of estrogens. Estrogens seem to protect neurons through the prevention of insult-induced decrease in phosphatase activity and the resulting neurotoxic, persistent hyperphosphorylation of proteins in multiple signaling pathways that are detrimental to cell survival. We have demonstrated that the neuroprotective effects of estrogen analogs against glutamate toxicity are opposed by phosphatase inhibition and that these analogs prevent insult-induced reduction in protein phosphatase levels as seen with 17␤-estradiol (Yi et al., 2005) . These data demonstrate that the protective effects of estrogens against neurotoxicity induced by oxidative stress and excitotoxicity are receptor-independent and involve protein phosphatase activation through a signal transduction pathway mediated by MAPK (ERK1/2). 8 . Phosphorylation of ERK after glutamate treatment in the presence and absence of ZYC3 and/or okadaic acid. Primary cortical neurons were treated with 50 nM okadaic acid (OA), 50 M glutamate (Glut), and/or 10 nM ZYC3. Cells were harvested after 24 h of treatment for Western blot analysis of pERK. The immunoblots for pERK1/2 were normalized to ERK2 to ensure equal protein loading, and these normalized data were used to depict the data as percentage of control (100%). Depicted are mean Ϯ S.E.M. for n ϭ 5. ‫,ء‬ p Ͻ 0.05 versus control. 
